These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 17093363)

  • 1. Pharmacology, pharmacogenetics, and clinical efficacy of 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting.
    Ho KY; Gan TJ
    Curr Opin Anaesthesiol; 2006 Dec; 19(6):606-11. PubMed ID: 17093363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytochrome P450 2D6 metabolism and 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting.
    Janicki PK
    Med Sci Monit; 2005 Oct; 11(10):RA322-8. PubMed ID: 16192915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
    Rubenstein EB
    Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of postoperative nausea and vomiting with granisetron and dolasetron in relation to CYP2D6 genotype.
    Janicki PK; Schuler HG; Jarzembowski TM; Rossi M
    Anesth Analg; 2006 Apr; 102(4):1127-33. PubMed ID: 16551910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylaxis of postoperative nausea and vomiting: controversies in the use of serotonin 5-hydroxytryptamine subtype 3 receptor antagonists.
    Kovac AL
    J Clin Anesth; 2006 Jun; 18(4):304-18. PubMed ID: 16797435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-HT3 receptor antagonists for prevention of late acute-onset emesis.
    Constenla M
    Ann Pharmacother; 2004 Oct; 38(10):1683-91. PubMed ID: 15316106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
    Hamadani M; Chaudhary L; Awan FT; Khan JK; Kojouri K; Ozer H; Tfayli A
    J Oncol Pharm Pract; 2007 Jun; 13(2):69-75. PubMed ID: 17873106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis: can we safely reduce the dose of administered agents?
    Aapro M; Blower P
    Cancer; 2005 Jul; 104(1):1-18. PubMed ID: 15929119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of 5-HT3 receptor antagonists for the prevention of postoperative nausea and vomiting after craniotomy: a meta-analysis.
    Neufeld SM; Newburn-Cook CV
    J Neurosurg Anesthesiol; 2007 Jan; 19(1):10-7. PubMed ID: 17198095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of 5-HT3 receptor antagonists for the prevention of postoperative vomiting following craniotomy: two studies in children and young adults.
    Neufeld SM; Newburn-Cook CV
    Can J Neurosci Nurs; 2009; 31(1):30-4. PubMed ID: 19397073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy of 5HT3-receptor antagonists in postoperative nausea and vomiting: the role of pharmacogenetics.
    Theodosopoulou P; Rekatsina M; Staikou C
    Minerva Anestesiol; 2023 Jun; 89(6):565-576. PubMed ID: 36852569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of neurokinin-1 receptor antagonists for the management of postoperative nausea and vomiting.
    Apfel CC; Malhotra A; Leslie JB
    Curr Opin Anaesthesiol; 2008 Aug; 21(4):427-32. PubMed ID: 18660647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients?
    de Wit R; Aapro M; Blower PR
    Cancer Chemother Pharmacol; 2005 Sep; 56(3):231-8. PubMed ID: 15838653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor.
    Rojas C; Stathis M; Thomas AG; Massuda EB; Alt J; Zhang J; Rubenstein E; Sebastiani S; Cantoreggi S; Snyder SH; Slusher B
    Anesth Analg; 2008 Aug; 107(2):469-78. PubMed ID: 18633025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same?
    Gan TJ
    CNS Drugs; 2005; 19(3):225-38. PubMed ID: 15740177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Granisetron: an update on its clinical use in the management of nausea and vomiting.
    Aapro M
    Oncologist; 2004; 9(6):673-86. PubMed ID: 15561811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetics of Postoperative Nausea and Vomiting.
    Aroke EN; Hicks TL
    J Perianesth Nurs; 2019 Dec; 34(6):1088-1105. PubMed ID: 31227296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis of the use of rescue antiemetics following PONV prophylactic failure with 5-HT3 antagonist/dexamethasone versus single-agent therapies.
    Kovac AL
    Ann Pharmacother; 2006 May; 40(5):873-87. PubMed ID: 16670361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of postdischarge nausea and vomiting after ambulatory surgery.
    Melton MS; Klein SM; Gan TJ
    Curr Opin Anaesthesiol; 2011 Dec; 24(6):612-9. PubMed ID: 21934496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic polymorphisms in the cytochrome P450 system and efficacy of 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting.
    Nielsen M; Olsen NV
    Br J Anaesth; 2008 Oct; 101(4):441-5. PubMed ID: 18782884
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.